A group of companies including King of Prussia-based CSL Behring are currently testing an experimental treatment for COVID-19 derived from the convalescent plasma of recovered patients, write Joseph Walker and Jared S. Hopkins for The Wall Street Journal.
The National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, is funding the study that will enroll 500 hospitalized patients across five continents. The trial will compare the new drug combined with Gilead Sciences’ antiviral medication remdesivir with a treatment of antiviral medication and a placebo.
The aim of the new drug that combines anti-coronavirus antibodies from multiple recovered patients is to make a more potent and effective form of convalescent plasma therapy than is typically derived from just one patient.
The patients will be followed for 28 days, which gives a study end date of sometime in early 2021, according to Bill Mezzanotte, CSL Behring’s global head of R&D and chief medical officer.
If the drug proves beneficial in improving patient symptoms, it can be used by several companies to seek approval for their specific hyperimmune products, said Mezzanotte.
Read more about CSL Behring at The Wall Street Journal by clicking here.
You Might Also Like